Trial Profile
Molecular Basket Trial In Multiple Malignancies With Common Target Pathway Aberrancies: A Phase II Trial of GSK2256098 and Trametinib in Patients With Advanced Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2022
Price :
$35
*
At a glance
- Drugs GSK 2256098 (Primary) ; Trametinib (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 31 Oct 2022 Status changed from active, no longer recruiting to completed.
- 12 May 2022 Planned End Date changed from 1 Sep 2021 to 1 Jan 2023.
- 01 Sep 2020 Planned End Date changed from 1 Dec 2019 to 1 Sep 2021.